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Abstract
Aim: Epac1−/− mice, but not Epac2−/− mice have elevated baseline permeability to
albumin. This study extends the investigations of how Epac‐dependent pathways modu-
late transvascular exchange in response to the classical inflammatory agent histamine. It
also evaluates the limitations ofmodels of blood‐to‐tissue exchange in transgenic mice in
DCE‐MRImeasurements.
Methods: We measured DCE‐MRI signal intensity in masseter muscle of wt and
Epac1−/−mice with established approaches from capillary physiology to determine how
changes in blood flow and vascular permeability contribute to overall changes of
microvascular flux. We used two tracers, the high molecular weight tracer (Gadomer‐17,
MW 17 kDa, apparent MW 30‐35 kDa) is expected to be primarily limited by diffusion
and therefore less dependent on changes in blood flow and the low molecular weight tra-
cer (Dotarem (MW 0.56 kDa) whose transvascular exchange is determined by both
blood flow and permeability. Paired experiments in each animal combined with analyti-
cal methods provided an internally consistent description of microvascular transport.
Results: Epac1−/−mice had elevated baseline permeability relative to wt control mice for
Dotarem andGadomer‐17. In contrast to wtmice, Epac1−/−mice failed to increase transvas-
cular permeability in response to histamine. Dotarem underestimated blood flow and vascu-
lar volume andGadomer‐17 has limited sensitivity in extravascular accumulation.
Conclusion: The study suggests that the normal barrier loosening effect of histamine in
venular microvessels do not function when the normal barrier tightening effect of Epac1
is already compromised. The study also demonstrated that the numerical analysis of
DCE‐MRI data with tracers of different molecular weight has significant limitations.
KEYWORD S
capillary permeability, compartment model, deconvolution, Dotarem, Epac1, histamine
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1 | INTRODUCTION
Investigations in cultured endothelial cell monolayers and
intact microvessels have demonstrated that cAMP depen-
dent Epac1 pathways modulate acute inflammatory
responses in endothelial barriers and exert a tonic action to
maintain normal baseline permeability.1,2 However, the
contribution of these pathways to vascular permeability
regulation in intact microvascular beds is less well under-
stood. The availability of mice with knockout of Epac1
and Epac2 has enabled us to study the role of the Epac
pathways in the intact microcirculation where the effects of
Epac pathways on both permeability and blood flow need
to be evaluated. We recently reported that Epac1−/− mice,
but not Epac2−/− mice, had elevated baseline permeability
to albumin.3 Furthermore, atrial natriuretic peptide (ANP),
a physiological modulator of vascular permeability,
increases the vascular permeability to albumin in wild‐type
(wt) mice as well as Epac2−/− mice. In contrast, the
Epac1−/− mice did not increase their permeability in
response to ANP above the already increased baseline.3
The primary aim of the present study was to use
Epac1−/− mice to evaluate the role of Epac‐dependent path-
ways in the modulation of transvascular exchange in
response to the classical inflammatory agent histamine.
Although genetically modified mice offer a wealth of
opportunities for extending advances in molecular and cel-
lular biology at the organ and organism level, there have
been few detailed investigations of microvascular
exchange, and in particular, the importance of plasma flow
and permeability in overall microvascular transport using
such animals. Some of the reasons for this include the
novel technical challenge of adjusting procedures and
detection sensitivity to the small animal size. Another is
the relative hyperdynamic circulation compared to larger
animals.4
Thus, a second aim of the present study was to explore
these physiological problems by extending previous meth-
ods using genetically modified mice with increased capil-
lary permeability and to use dynamic contrast‐enhanced
magnetic resonance imaging (DCE‐MRI).3,5 We used two
tracers with different molecular weight to measure tissue
uptake under conditions where blood flow and vascular
permeability were increased by histamine. The transport of
the high molecular weight tracer Gadomer‐17 (MW
17 kDa and apparent MW 30‐35 kDa) across the microvas-
cular wall is expected to be primarily limited by diffusion
in mouse masseter muscle and therefore less dependent of
changes in blood flow. The lower molecular weight tracer
was Dotarem (MW 0.56 kDa) for which the exchange is
determined by both blood flow and permeability.6
We have evaluated numerical methods to account for
rapid changes in the arterial tracer concentration (so‐called
blind deconvolution) and compartmental models that
describe both diffusion limited and flow limited exchange,
as well as exploit the fact that DCE‐MRI enables repeated
measurements days apart using tracers of varying molecular
weights. The DCE‐MRI is combined with numerical analy-
sis as described in Methods using the Johnson‐Wilson
model for capillary exchange7 based on the classical Kety/
Renkin/Crone model of tracer extraction in a perfused
microvessel as well as a compartmental model where the
ratio of local vascular volume and exchange area is
assumed to remain fixed as blood flow changes.
The main conclusion from the present study is that
Epac1−/− mice have elevated baseline permeability relative
to wt (C57black) control mice to Dotarem as well as Gado-
mer‐17. In contrast to wt mice, Epac1−/− mice failed to
increase their microvascular permeability in response to
histamine. This suggests that the barrier loosening effect of
Epac1−/−is already at the maximum that histamine would
cause in wt mice. The study demonstrates that paired
sequential experiments using more than one tracer in each
animal combined with analytical methods provide a more
internally consistent description of modulations of
microvascular function than experiments using only one
tracer and unpaired experimental design. Finally, the study
also demonstrated that the numerical analysis of DCE‐MRI
data with tracers of different molecular weight has signifi-
cant limitations.
2 | RESULTS
2.1 | Overview of data and analyses of tracer
signal intensity curves in mice
Before we describe the results that address changes in vas-
cular permeability, surface area for exchange and blood
flow in response to histamine in wt and Epac1−/− mice, we
first describe the general form of the signal intensity (SI)
curves from the contrast‐enhanced MRI measurements used
to obtain these exchange parameters. For all experiments,
we placed a region‐of‐interest (ROI) over the masseter
muscle away from any large blood vessel to fulfil the
assumptions in the model that the SI signal was mainly
determined by exchange in small microvessels with diame-
ter of 5‐15 μm. Figure 1 shows the SI curves from paired
experiments in a wt mouse where the low molecular weight
MRI contrast agent Dotarem (MW 0.56 Kd) was injected
via the tail vein 1.5 minutes after saline (control) (black
squares) and then, 24 hours later, 1.5 minutes after his-
tamine (blue squares). The shape of SI curves was the
same for all experiments. With a bolus injection of tracer
(176 μL within 15 seconds), there was an initial step
increase in SI followed by a further SI increase as addi-
tional tracer crossed the vascular wall and accumulated in
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the tissue. SI continued to increase because the concentra-
tion difference between plasma and the extravascular space
favoured plasma‐to‐tissue diffusion. Plasma tracer concen-
trations fell as Dotarem diffused into all the mouse tissues
and was excreted by filtration in the kidney. Tracer accu-
mulation in the tissue reached a peak when the fall of vas-
cular tracer concentration was sufficient for the tracer to
begin to diffuse back out of the tissue compartment.
2.2 | Fitting Signal Intensity (SI) curves for
Dotarem and Gadomer‐17 using the
Compartmental Model
Figure 1 shows that the time to complete a step increase in
tracer concentration was at least 20 seconds (up to 3 circu-
lation times in the mouse). The curves in Figure 1 were
obtained by integrating the expression for Fick's Law of
Diffusion as described in the Methods taking into account
the fall in vascular tracer concentration. Model curves that
best described the entire time course of the tracer were
used to evaluate a characteristic time constant for tracer
exchange between plasma and tissue (PS/Va) where PS is
the permeability‐surface area product for the tracer and Va
is the local vascular volume.
The fall in vascular tracer concentration within the mea-
suring window was described by two time constants as out-
lined in Methods. One accounted for equilibration of tracer
into all the tissues of the body and the other for renal
excretion of the tracer. In Figure 1, the half‐time for the
vascular tracer (broken black curve) was 37 seconds for
control experiments and 23 seconds after histamine (broken
blue curve). These values were consistent with independent
estimates of the half‐time of intravascular Dotarem in wt
mice using the deconvolution analysis (see Tables 1 and
2). As noted in Methods, the second rate constant was
included to account for renal excretion of Dotarem by
glomerular filtration based on measurement of glomerular
filtration rate. Renal excretion was not included for the lar-
ger Gadomer‐17 tracer. It is noted that there was always
some discrepancy between the model prediction and the
measured tissue SI during the first 20‐30 seconds after
injecting the tracer, reflecting, at least in part, the limitation
of describing the initial vascular filling as a step increase
in tracer amount.
The use of the compartmental model to analyse SI
curves using the larger Gadomer 17 as the tracer was much
simpler because the time constants for tracer fall were
found to be more than ten times longer than for Dotarem
and tracer accumulation in tissue increased more slowly.
2.3 | Fitting SI curves for Dotarem and
Gadomer‐17 using the Johnson‐Wilson model
and deconvolution
An unexpected result was that we had far more problems
with the analysis based on the Johnson‐Wilson model and
the advanced curve fitting (deconvolution) analysis than
with the compartmental model. As described in the Meth-
ods, we first estimated the four primary model parameters:
intravascular transit time Tc, plasma flow Fp, extraction
fraction E and kep, a tissue to plasma rate constant for
exchange. The values of the plasma volume Va, extravascu-
lar volume Ve and permeability‐surface area product PS are
derived from these directly estimated parameters and are
therefore not independent parameters. An important result
indicating limitations of this approach was that estimates of
Fp and Va using Dotarem and Gadomer‐17 were signifi-
cantly different (see Tables 1 and 2 below where plasma
flows are reported as equivalent blood flows). These values
should have been the same for the two tracers under the
same perfusion conditions. Furthermore, Gadomer‐17
extraction fractions fell below 0.1 in contrast to Dotarem
(extraction fraction >0.5). This limited the sensitivity of
the Gadomer‐17 to the changes in extravascular tracer
accumulation. However, because Gadomer‐17 was to a lar-
ger extent retained in the vascular space, it was a more reli-
able vascular tracer. In the legends to Tables 1 and 2, we
have indicated the parameters whose values are least
FIGURE 1 MRI signal intensity in
control (i.v. saline) and after histamine
administration represented as black and
blue squares respectively. Also shown are
results when using the two compartment
model for tissue concentration (solid line)
and in plasma (Ca, dashed line) with black
and red representing saline and histamine
administration respectively
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reliable. In spite of these limitations, we have demonstrated
a clear difference in the response of Epac1−/− mice to his-
tamine compared to wt controls as described below.
2.4 | Response to histamine in wt and
Epac1−/− mice: compartmental analysis using
Dotarem
The primary rate constant from the analysis is the ratio PS/
Va where Va is the local plasma volume. In wt mice, PS/Va
increased from 0.025 ± 0.006 s−1 to 0.053 ± 0.011 s−1
(P < 0.001) with histamine. In Epac1−/− mice, the baseline
value of PS/Va was 0.036 ± 0.007 s
−1 and was signifi-
cantly increased compared to wt saline controls but his-
tamine did not increase PS/Va further (0.040 ± 0.006 s
−1).
Figure 2 summarizes the estimates of the permeability coef-
ficients (Ps) calculated from the mean rate constants from
the paired experiments (saline control vs histamine) for
Dotarem in wt and Epac1−/− mice. The permeability coeffi-
cients in Figure 2 are calculated assuming an average value
FIGURE 2 Permeability (Ps) for
Dotarem in wild‐type (wt) mice and
Epac1−/− mice in control (i.v. saline) and
after histamine administration determined
with the two compartment model.
***P < 0.001 for histamine vs control.
##P < 0.01 and ###P < 0.001 for the same
situation comparing between wt and
Epac1−/−
FIGURE 3 A (Upper panel),
Recording of MRI‐signal (black circles)
after Gadomer‐17 in control (i.v. saline)
and analysed with the two compartment
model. Solid and dashed lines represent
modelling of tissue data and arterial
concentration (Ca) respectively. B (Lower
panel), Recording of MRI‐signal recording
(blue circles) after Gadomer‐17 and
histamine administration and analysed with
the two compartment model. Solid and
dashed lines represent modelling of tissue
data and arterial concentration (Ca)
respectively
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for the ratio of vascular volume to surface area (Va/S) of
4.4 × 10−4 cm as described in Methods. According to this
analysis, histamine increased the Dotarem permeability
coefficient in wt mice from 11.1 ± 2.6 to
23.5 ± 4.7 × 10−6 cm s−1 (P < 0.001). The baseline per-
meability to Dotarem in Epac1−/− animal in control was
15.8 ± 0.9 10−6 compared to 11.1 ± 2.6 × 10−6 cm s−1 in
wt (P < 0.01). However, in Epac1−/− mice, histamine did
not significantly increase the permeability coefficients to
Dotarem (17.6 ± 2.6 × 10−6 cm s−1 vs the elevated base-
line of 15.8 ± 0.9 × 10−6 cm s−1).
2.5 | Wild type vs Epac1−/− using Gadomer‐
17 and the two‐compartmental model
Figures 3A,B show one example to fit paired measure-
ments of the tissue uptake curve for Gadomer‐17 with and
without histamine in a wt mouse. The mean half‐times for
the fall in arterial concentration were 339 s−1 with saline
and 190 s−1 after histamine administration. This was deter-
mined by the requirement to simultaneously fit the initial
tracer accumulation after Gadomer‐17 filling of the vascu-
lar space and the time after the total tissue tracer accumula-
tion began to fall as the Gadomer‐17 equilibrated with
other tissues in the body.
Reliable values for PS/Va for Gadomer‐17 with saline and
histamine treatment were obtained from seven of eight wt
mice tested. Ps was estimated assuming Va/S was 4.4 × 10
−4
as for the Dotarem. Histamine increased mean Ps for Gado-
mer‐17 from 1.76 ± 0.5 × 10−6 to 2.8 ± 0.6 × 10−6 cm
s−1. The SI curve from the Epac1−/− mice was more variable,
and reasonable data from paired experiments with saline and
histamine treatment were from 8 of 14 mice. Figure 4 sum-
marizes the results using the compartmental method in the
successful experiments. Histamine significantly increased
baseline permeability in wt mice. The baseline permeability
to Gadomer‐17 was also significantly increased in Epac1−/−
mice (3.4 ± 0.6 × 10−6), but histamine did not increase per-
meability further (Ps = 3.6 ± 0.6 × 10
−6 cm s−1). Thus, the
analysis of Gadomer‐17 data using the compartmental model
was also consistent with the observations when using
Dotarem and demonstrated that histamine did not increase
permeability in Epac1−/− mice above the already elevated
(relative to wt mice) baseline permeability.
2.6 | Response to histamine in wt mice
compared to Epac1−/− using Dotarem and the
Johnson‐Wilson model
Table 1 summarizes the primary variables Tc, Fp, E and kep
together with the additional parameters derived from these
variables when the Johnson‐Wilson analysis is applied to
the same data as in Figure 1. This analysis confirms a sig-
nificant difference in the response of Epac1−/− mice rela-
tive to wt mice after exposure to histamine. Histamine
increased Dotarem tracer delivery and tissue uptake in wt
mice as indicated by increased blood flow, reduced
transvascular transit time (Tc), and increased tissue to
plasma exchange measured as the coefficient kep. The clear
differences between wt mice and Epac1−/− mice are high-
lighted by comparing transvascular transit times (Fig-
ure 5A) and the exchange coefficient (kep) (Figure 5B). In
contrast to the action of histamine in wt mice (Figure 5A),
histamine causes no further increase in the rate constant of
tracer exchange, kep, in Epac1
−/− mice compared with the
saline controls in these animals (Figure 5B). Further, kep in
the saline controls in Epac1−/− mice are significantly
increased relative to the wt controls (0.55 ± 0.07 min−1 vs
0.44 ± 0.09 min−1, P < 0.01). In Epac1−/− mice, there is
no significant change in intravascular transit time, Tc, rela-
tive to wt controls and Tc after exposure to histamine, was
still 83% of saline control. To summarize, the Johnson‐Wil-
son deconvolution analysis demonstrated that the saline
controls in Epac1−/− mice have an increased tracer
FIGURE 4 Permeability (Ps) for
Gadomer‐17 in wild‐type (wt) mice and
Epac1−/− mice in control (i.v. saline) and
after histamine administration determined
with the two compartment model and the
slope/step method. **P < 0.01 for
histamine vs control and ##P < 0.01 and
###P < 0.001 for the same situation
comparing within wt and Epac1−/−
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exchange (kep) and unchanged intravascular transit time
(Tc). Histamine failed to modify these parameters in
Epac1−/− mice compared to wt mice where kep increased
and Tc decreased.
Although this analysis confirms the failure of Epac1−/−
mice to increase exchange above an elevated baseline, the
mechanisms contributing to the attenuated response to his-
tamine require an analysis of changes in blood flow and per-
meability. We note that the JW analysis appears to weight
towards increased blood flow. For example the histamine
response in wt mice is accounted for by a doubling of plasma
flow with no change in PS, but the extraction fractions in tis-
sue (0.71 ± 0.05 vs 0.51 ± 0.08) do not fall as much as
expected for no change in PS. Further, while kep is increased
in Epac1−/− saline controls relative to wt controls
(0.56 ± 0.07 min−1 vs 0.44 ± 0.09 min−1, P < 0.01) this is
not accounted for by any change in PS or flow. Finally, the
values of blood flow and vascular volume are low compared
to published values <10.l mL min−1 100 mL−1 vs >20 mL
min−1 100 mL−1 in several published studies.8–10 These
observations are evaluated further in Discussion.
2.7 | Dotarem vs Gadomer‐17 in wt mice
with Johnson‐Wilson model
As a step towards using Gadomer‐17 as a test tracer in the
Johnson‐Wilson analysis, we first carried out paired mea-
surements of both Dotarem and Gadomer‐17 on the same
TABLE 1 Effect of histamine in wild‐type and Epac1−/− mice using Dotarem and studied by DCE‐MRI (MW 0.56 kDa). The results are
based on repeated measurements, i.e. after control measurements with i.v. saline a new measurement was performed 1 day later using i.v.
histamine administration. The Johnson‐Wilson deconvolution model was used for calculation. The confidence of blood flow and blood volume
are evaluated in Discussion
Wild type_(n = 7) Epac1−/− (n = 10)
Saline Histamine Saline Histamine
Primary derived parameters
Blood flow (Fb), mL 100 mL
−1 min−1 6.27 ± 1.16 11.81 ± 1.64*** 6.81 ± 1.06 9.1 ± 3.64
Efflux rate from Ve, to Vb (kep), min
−1 0.443 ± 0.087 0.691 ± 0.074*** 0.555 ± 0.071## 0.478 ± 0.148*
Extraction fraction 0.739 ± 0.053 0.516 ± 0.037*** 0.715 ± 0.047 0.590 ± 0.081**,#
Intravascular transit time (Tc), seconds 17.6 ± 3.05 8.79 ± 2.02*** 14.0 ± 3.64 11.6 ± 2.39
(#)
Plasma t1/2, seconds 36.7 ± 8.2 22.6 ± 17.1*** 25.9 ± 6.0
# 21.1 ± 5.2*
Secondary derived parameters
Blood volume (Vb), mL 100 mL
−1 1.82 ± 0.38 1.70 ± 0.27 1.58 ± 0.41 1.70 ± 0.70
PS, mL 100 mL−1 min−1 6.08 ± 1.21 6.16 ± 0.49 6.11 ± 0.42 5.83 ± 2.72
Extravascular space (Ve), mL 100 mL
−1 10.44 ± 1.45 8.85 ± 0.89*** 8.81 ± 1.35# 11.7 ± 6.30#
Transfer constant Vb to Ve (ktrans), min
−1 3.32 ± 0.60 4.36 ± 0.41*** 3.48 ± 0.38 3.80 ± 1.59
Mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001 histamine vs control; #P < 0.05, ##P < 0.01 same condition comparing wt vs Epac1−/−. (#)P = 0.052.
Dotarem Gadomer‐17
Primary derived parameters
Blood flow (Fb), mL 100 mL
−1 min−1 7.47 ± 1.84 16.60 ± 7.80*
Intravascular transit time (Tc), seconds 11.7 ± 3.00 11.7 ± 3.00
cf legend
Extraction fraction 0.657 ± 0.043 0.074 ± 0.027***
Efflux rate from Ve, to Vb (kep), min
−1 0.613 ± 0.109 0.225 ± 0.078***
Plasma t1/2, seconds 20 ± 4 637 ± 507*
Secondary derived parameters
Blood volume (Vb), mL 100 mL
−1 1.39 ± 0.26 2.94 ± 0.81**
PS, mL 100 mL−1 min−1 5.67 ± 0.90 0.83 ± 0.28***
Extravascular volume (Ve), mL 100 mL
−1 7.98 ± 1.30 4.96 ± 0.95**
Transfer constant Vb to Ve (ktrans), min
−1 3.49 ± 0.68 0.79 ± 0.27***
Mean ± SD. *P < 0.05, **P < 0.01 and ***P < 0.001 for Dotarem vs Gadomer‐17.
TABLE 2 Comparison of Dotarem
(MW 0.56 kDa) and Gadomer‐17 (MW
17 kDa and apparent MW 30‐35 kDa) in
six wt mice where Dotarem was injected
first and Gadomer‐17 was injected 1 day
later. Johnson‐Wilson deconvolution
method was used for calculation in these
experiments. Intravascular transit times
(Tc) from the Dotarem were used in the
Gadomer‐17 experiments in order for the
model to converge and provide a
solution. The confidence in the reported
values of blood flow and volume for
Dotarem and Extraction reaction for
Gadomer‐17 are evaluated in Discussion
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wt mouse (Table 2). The Johnson‐Wilson deconvolution
analysis required that the transit time for the two tracers be
the same for successive iterations to converge. There are
several key observations from the data presented in
Table 2. As expected in these wt mice, the estimate of kep
for the higher molecular weight tracer Gadomer‐17 was
less than that for Dotarem (0.22 ± 0.08 vs
0.61 ± 0.1 min−1) and the half‐times for the fall of arterial
tracer concentration were nearly 30 times longer for Gado-
mer‐17 than for Dotarem. Further, the extraction fraction
for Gadomer‐17 was <0.1 consistent with significant diffu-
sion‐limited exchange. A striking result was that the esti-
mate of resting blood flow using Gadomer‐17 is more than
twice that obtained when using Dotarem (16.7 vs 7.5 mL
min−1 100 mL−1, P < 0.05). The corresponding estimate
of local blood volume for Gadomer‐17 was also twice that
for Dotarem (2.9 ± 0.8 vs 1.4 ± 0.4 mL 100 ml−1,
P = 0.01). As noted above, both blood flow and local
blood volume should be independent of the molecular
weight of the tracer and this result points to the Johnson‐
Wilson deconvolution model as the source for the discrep-
ancy.
In six additional experiments, the action of histamine on
tissue uptake of Gadomer‐17 was tested in wt mice.
Histamine significantly increased the plasma flow (from
14.4 ± to 25.2 mL min−1 100 mL−1) and reduced transit
times in wt mice. Extraction fraction fell from 0.080 to
0.038. However, there was no significant increase in the
model estimates of kep, ktrans or PS. These results indicate
either that histamine unexpectedly failed to increase vascu-
lar permeability to Gadomer‐17, or that the Johnson‐Wilson
model has reduced sensitivity to detect changes in perme-
ability when extraction fractions fell below 0.1. This limita-
tion is supported on theoretical grounds as described in the
Discussion. Because of these limitations, the further analy-
sis of Gadomer‐17 tissue SI data using the Johnson‐Wilson
model is not reported.
3 | DISCUSSION
The result that histamine significantly increases vascular
exchange in the wt mice, but fails to increase vascular
exchange above the already increased baseline level in the
Epac1−/− mice is similar to that described in previous
experiments using ANP in wt mice and Epac1−/− mice.
Taken together these observations conform to the hypothe-
sis that changes in the Epac1 pathways that maintain nor-
mal vascular permeability modify the response to
FIGURE 5 A (Upper panel),
Intravascular transit time (Tc) for Dotarem
in wild‐type (wt) mice and Epac1−/− mice
injected with i.v. saline (control) and after
histamine administration. ***P < 0.001 for
histamine vs control (saline). #P < 0.05 for
the same condition comparing between wt
and Epac1−/− (#P = 0.052 for control wt vs
Epac1−/−, P = 0.059 for Epac1−/− saline
(control) vs histamine). B (Lower panel),
Rate constant for transport from the
extravascular to the intravascular space (kep)
for Dotarem in wt mice and Epac1−/− mice
injected with i.v. saline (control) and after
histamine administration. ***P < 0.001 for
histamine vs control and ##P < 0.001 for
the same situation comparing within wt and
Epac1−/−
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inflammatory agents. Before discussing the mechanisms
that may underlie these differential responses to histamine
of wt and Epac1−/− mice, we evaluate the novel aspects of
the present experimental approach. It involves the determi-
nation of rate constants for vascular exchange and other
key vascular perfusion parameters in paired experiments
with and without histamine on the same animal. The pre-
sent approach using both low molecular weight Dotarem
and higher molecular weight Gadomer17 provide new ways
to evaluate strengths and weaknesses of analyses of tissue
tracer accumulation based on DCE‐MRI imaging
approaches. The two most important vascular parameters to
be measured to understand vascular exchange are plasma
flow (Fp) and PS. The assumptions made in the Johnson‐
Wilson model and the simplified two‐compartmental model
introduce uncertainties into the estimates of Fp and PS. We
evaluate the issue first with respect to PS.
3.1 | Johnson‐Wilson model evaluation:
evaluation of permeability
Plasma‐to‐tissue exchange is estimated as a flux in the John-
son‐Wilson model and depends on the permeability coeffi-
cient of the vascular wall (Ps) the surface area for exchange
(S) and blood flow (Fb). The model measures only the pro-
duct of permeability coefficient and surface area which is
conventionally written as PS. The data in Figures 3A,B
demonstrate that Gadomer‐17 accumulation after histamine
administration (Figure 3B) was at least as rapid as the saline
control even though arterial tracer concentration was falling
more rapidly after histamine i.e. there were smaller plasma‐
to‐tissue tracer concentration differences). Under these con-
ditions, the compartmental model (which weighted the whole
curve) conservatively described a 50% increase in the rate
constants for blood‐to‐tissue exchange with histamine. We
can compare this observation with the expected increase in
tracer uptake if there was an increase in blood flow with no
change in PS. For values of PS/Fp of the order of 0.1, the
fractional increase in tracer uptake calculated as
Fp(1−exp−(PS/Fp)) with no change in PS would be <5%
increase if flow increased 1.8‐fold as observed (i.e. 25.3 after
histamine vs 14.4 mL min−1 100 mL−1 in control). Thus,
most of the increase in Gadomer‐17 exchange described in
Figure 3 was the result of increased Ps. Further, the observa-
tion that no increase in PS after histamine was measured
using the Johnson‐Wilson model is consistent with the con-
clusions in the original Johnson‐Wilson paper.7 Specifically,
Figure 4 of their paper shows that venous tracer concentra-
tion (Cv) is very close to Ca when values of PS/Fp (α in their
paper) are of the order of 0.1 and the difference (Ca−Cv)
used to estimate extraction fraction approach zero.
Further, as we noted above, the tissue intensity signals
from experiments using histamine and Gadomer‐17 were
less stable, and likely added to the problems by introducing
significant variability in estimates of the half‐time for the
fall in arterial tracer concentration in the AIF and limiting
convergence of the deconvolution protocol. Overall, the
Johnson‐Wilson model approach is most appropriate for
highly diffusible tracers. Most of the detailed analysis of
the model in the original Johnson‐Wilson paper focuses on
PS/Fp values much larger than 1 (and in the range 5‐50).
In contrast, as noted above, PS/Fp for Dotarem falls closer
to the range when the Johnson‐Wilson model can be more
reliably applied (0.4‐1).
3.2 | Johnson‐Wilson model evaluation:
blood flow and blood volume
One clear result was that the measured values of vascular
volume and plasma differed significantly between Gado-
mer‐17 and the lower molecular weight tracer Dotarem.
For example, when measured plasma flows are converted
to blood flows using a haematocrit of 40%, resting local
blood flows estimated using Dotarem in wt mice averaged
7.5 mL min−1 100 mL−1 tissue, which is half those esti-
mated from Gadomer‐17 (average 16.6 mL min−1
100 mL−1; Table 2). Further, local blood volumes esti-
mated for Dotarem are also around half those estimated
using Gadomer‐17 with the respective average numbers of
1.4 compared with 2.9 mL 100 mL−1 tissue based on
Gadomer‐17 (Table 2). The published values for resting
plasma flow in muscle are of the order of 20 mL min−1
100 mL−1 or larger8–10 and the microvascular blood vol-
ume expected for a measured surface area of 7 × 103 cm/
100 g tissue for dilated skeletal muscle is greater than
3 mL 100 mL−1 (calculated using the same mean volume
to surface ratio of 4.4 × 10−4 cm in all our calculations
above). In previous investigations using radiolabelled albu-
min as a tracer, we found no difference between the local
vascular volumes in muscle tissue in Epac1−/− mice and wt
mice.3 The most likely reason that Gadomer‐17 appears to
provide more reliable estimates of vascular parameters is
that it is retained within the vascular space to a larger
extent than Dotarem during the measuring period. One
example of this is that half‐times for arterial tracer concen-
tration of Gadomer‐17 are several hundred seconds com-
pared to just tens of seconds for Dotarem (see also11).
From available data on cardiac output and blood volume,
the circulation time is between 7 and 10 seconds in a
mouse, allowing for blood volume to be circulated for at 6‐
10 times in a minute.4 With half‐times of the order of 20‐
37 seconds for the fall in arterial Dotarem concentration
there could be significant loss of the tracer before com-
pletely uniform mixing of the Dotarem. Comparable losses
with Gadomer‐17 with half‐time more than an order of
magnitude greater are much less significant. We note,
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however we cannot rule a bias introduced into Gadomer‐17
measurement due to the fact that the volume of Gadomer‐
17 contrast agent infused was larger than Dotarem (300 vs
120 μL) and the whole vascular volume transiently
expanded more in the presence of Gadomer‐17 than
Dotarem. It would not be surprising if the combination of
slightly increased vascular volume and low extraction frac-
tion also contributed to a bias of the JW analysis towards
larger overestimates of blood flow.
3.3 | Simplified two‐compartmental model:
Ps and the neglect of flow effect
The compartmental model applied to the Dotarem data also
has clear limitations because it does not directly describe
changes in plasma flow and concentration gradients along
the microvessels are ignored. Nevertheless, the range of
uncertainty in the estimation of PS can be calculated for
the expected range of PS/Fb. A key assumption in the sim-
plified two compartment model is that the mean tracer con-
centration in the exchange microvessels is equal to the
arterial concentration. This is, however, not valid when
there is an arterial to venous gradient of concentration
along the exchange vessels. Failure to account for the gra-
dient of tracer concentration along the blood vessels would
lead to an underestimate of Ps. For Dotarem, the worst case
is to use values based on the low estimates of Fb in wt
mice from Table 1, which gives PS/Fp close to 1 in control
for wt mice. In this situation, venous concentration would
be as low as 37% of the arterial concentration and a mean
concentration in the exchange vessel close to 70% of arte-
rial concentration. Thus, Ps could be underestimated by
about 30%. However, if blood flows were twofold larger
(as measured with Gadomer‐17), the underestimate would
be closer to 20%.
An additional assumption in the compartmental model
is that permeability coefficients (Figures 2 and 4) can be
calculated from the rate constants (PS/Va), assuming a rea-
sonable value for Va/S which is also unchanged even when
blood flow increases. The latter assumption is valid, for
example, if histamine increased the number of exchange
microvessels that were perfused, but the distribution of the
increased blood flows between small and larger microves-
sels after histamine was the same as saline control. On the
other hand, if histamine‐induced vasodilation increased sur-
face area for exchange (S) more than it increases local vas-
cular volume (Va), Va/S after histamine should be smaller,
and the use of a constant value of Va/S would overestimate
Ps after histamine relative to controls. This would be the
case if histamine‐induced vasodilation results in more small
diameter capillaries being perfused compared to the number
of perfused venular microvessels. For example, if the sur-
face area of perfused capillaries doubled relative to venular
vessels, Va/S would be reduced from 4.4 × 10
−4 cm to
close to 3.3 × 10−4 cm and Ps would be overestimated by
close to 33%. Thus, likely errors in the compartmental
model for Dotarem range from an underestimate of close to
30% (due to arterio‐venous gradients) to an overestimate of
a similar magnitude due to redistribution of flow. If both
sources of error were present, they may cancel each other.
Finally, we can use the same approach as described
above using Gadomer‐17 to evaluate the contributions of
increased blood flow and increased PS to the histamine
response with Dotarem. For PS/Fb close to 0.5 (a maxi-
mum value from Table 1 in the presence of histamine),
increased blood flow with no increase in the value of PS
would account for about 25% of tissue uptake. This is less
than the twofold increase in tracer uptake of Dotarem
shown in Figure 1. Thus, we conclude that both diffusion
and flow contribute significantly to tissue uptake of
Dotarem.
3.4 | Mechanisms of action of histamine in
wild type vs Epac1−/− mice
The difference between wt and Epac1−/− mice may be
understood in terms of the action of how Epac1 pathways
maintain normal permeability in all microvessels (capillar-
ies and venular microvessels) by stabilizing cell‐cell adhe-
sion.1,2 We have already shown that Epac1 pathways
maintain the in vivo basal state permeability and the den-
sity of endothelial cell adhesions in the microvessels of
major tissues like skin and skeletal muscle.3 An important
permeability‐promoting action of histamine is to increase
the tension within the endothelial cells forming the walls of
venular microvessels.2,12 We expected, considering the
weaker intercellular adhesion in the capillary wall of the
Epac1‐deficient mice, that histamine would increase the
permeability of Epac1−/− endothelium beyond that
observed in wt mice in the basal state. The present study
showed, contrary to this expectation, that histamine did not
increase further the microvascular passage of MRI‐active
probes in the Epac1−/− mice.
In fact, histamine alone led to a similar increase in
microvascular permeability as Epac1 deletion, but had no
additional effect in the Epac1−/− microvasculature. It
appears therefore that the elevated baseline permeability of
masseter muscle Epac1−/− microvessels was already near
the maximum induced by histamine. A strong cAMP stim-
ulation can blunt the permeability‐enhancing effect of his-
tamine in some microvascular systems.12,13 This suggests
that histamine and cAMP may act via opposing mecha-
nisms. A recent study implicates the adherens junctions as
being pivotal for the histamine‐induced tension of endothe-
lial cells. The proposed mechanism is that the fibres
induced to contract by histamine require anchoring to intact
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adherens junctions to achieve widening of the intercellular
cleft.14 A working hypothesis that may explain previous
observations by others as well as the present findings is
therefore that histamine acts to widen the clefts between
endothelial cells mainly when they have near basal cAMP/
Epac1 stimulation. In the absence of Epac1, the contractile
fibres stimulated by histamine may lack strong anchoring
to adherent junctions. On the other hand, at very high
Epac1 (and PKA) activation, the adherens junctions may
be too tight for the histamine‐induced contractile fibres to
widen substantially the intercellular cleft. We note that our
previous observation that ANP fails to increase permeabil-
ity above elevated baseline values suggests that changes to
the tethering of molecular complexes at adherens junctions
of Epac1−/− mice are likely to account for our observations
with both histamine and ANP.
3.5 | Further applications
On a more technical note, the study demonstrates that
paired sequential experiments using more than one tracer in
each animal combined with analytical methods provide a
more internally consistent description of modulations of
microvascular function than experiments using only one
tracer and unpaired experimental design. The study also
demonstrated that the numerical analysis of DCE‐MRI data
with tracers of different molecular weight has significant
limitations.
Finally, we note that the ongoing development and
evaluation of methods to apply DCE‐MRI imaging to the
evaluation of microvascular functions focuses not only on
muscle tissue in mouse models as described here, but also
transvascular exchange in tissue with widely different per-
meability and blood flows. A recent study used DCE‐
MRI and Dotarem to study the blood‐brain barrier in
patients and described several different models including
versions of the compartmental model used above for fit-
ting the MRI data.15 The conclusion was that the Patlak
model accounting for simultaneous diffusion and convec-
tion best fitted their observations on the human blood‐
brain where the vascular permeability coefficients are up
to two orders of magnitude smaller than muscle and
where the human circulatory system is less hyperdynamic
compared to mice (e.g. heart rate up to 600 beats/min).
On the other hand, an important area for both experimen-
tal and clinical investigation is the tumour vasculature.
There is evidence that altered microvascular permeability
is an early sign of neoplastic growth which correlates
with the degree of malignancy of solid tumours.16–18 In
tumours, a wider range of plasma flows, vascular perme-
ability and high levels of vascular heterogeneity than
encountered in the present study is likely. The limitations
for the use of DCE‐MRI as demonstrated for masseter
muscle in this study may not be the same for such differ-
ent applications. Nevertheless, the careful evaluation of
the tissue SI curves using separate tracers and comple-
mentary analyses as illustrated using Gadomer‐17 and
Dotarem are likely to provide more reliable information
that studies based on a single tracer and one method of
analysis. An important message from this study is that the
tracer used for DCE‐MRI must be tailored towards the
permeability characteristics of the tissue and vascular bed
that is to be studied.
4 | MATERIALS AND METHODS
4.1 | Ethical approval
Animal experiments were approved by the Norwegian Ani-
mal Research Authority (approval number 4894). The study
was conducted according to the European Convention for
the Protection of Vertebrates Used for Scientific Purposes,
Norway. The study was performed at the Department of
Biomedicine and the Molecular Imaging Facility at the
University of Bergen, Norway.
4.2 | Animal experiments
4.2.1 | Wild type and Epac1−/− mice
Generation of Epac1−/− mice has been described in detail
elsewhere.3 Briefly, heterozygous floxed Rapgef3 mice were
generated at the Mouse Clinical Institute, Strasbourg, France.
They were subsequently crossed with C57BL/6J mice
expressing CRE recombinase from the CMV promoter
resulting in global deletion of Epac1 expression, as con-
firmed by immunoblotting and RT‐PCR.3 C57BL/6JBomTac
mice from Taconic, Denmark, were used to backcross the
recombined chimeric mice for at least 10 generations.3
C57Black were used as controls for the Epac1−/− mice.
4.2.2 | General
The animals were kept with artificial lighting on a 12:12‐
hour light‐dark cycle. Room temperature was kept con-
stant at 23°C, and the animals were provided with water
and rodent chow ad libitum. The mice were 8‐10 weeks
old when used for experiments. The weight range was
19‐21 g and an equal number of male and female mice
were used. All experimental procedures were performed
while animals were anaesthetized as described below. A
single i.v. catheter (polyethylene, i.d. 0.28 mm and o.d.
0.61 mm, Portex, Smiths Medical International Ltd, Kent,
UK) was connected to a 30G insulin syringe (Omnican,
B. Braun Melsungen, Melsungen, Germany) and placed in
a tail vein.
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4.2.3 | Dynamic‐contrast enhanced magnetic
resonance imaging of the masseter muscle
During scanning, the mice were anaesthetized using
3.0 ± 1.0% sevoflurane mixed with oxygen at a flowing rate
of 200 cc/min. Respiration rate and body temperature were
monitored using MRI‐compatible animal monitoring equip-
ment (SA Instruments, Stony Brook, NY, USA). Respiration
averaged around 60‐80 cycles/min, but increased, sometimes
as much as twofold, immediately after the injection of his-
tamine. The core body temperature was kept at 35 ± 1°C.
The depth of anaesthesia was evaluated by toe pinch prior to
starting placing the intravenous catheter in the tail and from
the respiration frequency (60‐80 per min) during scanning.
The time required for the scanning was 25 min. During the
first scanning session, the mice received saline i.v. After the
scanning, the i.v. line was removed and the mice woke up.
The next day they were re‐anaesthetized and a new venous
catheter was introduced in the tail vein. The mice then
received histamine instead of saline and the scanning was
repeated with the same parameter settings as the first day. At
the end of the procedure and while still anaesthetized, the
mice were killed by breaking their stretched neck with a
blunt stroke with a pair of scissors.
The MRI experiments were performed on a 7T horizon-
tal‐bore preclinical scanner (Pharmascan 70/16; Bruker
Corporation, Karlsruhe, Germany), using a 23 mm ID
mouse‐head quadrature volume resonator in a single‐coil
(TX/RX) configuration. Estimation of microvascular
haemodynamic parameters was based on a 2D FLASH
acquisition with a 17‐degree flip angle and 1400 image
frames with a time resolution of 1.080 seconds. The total
scan time was therefore 25 minutes 12 seconds. In addi-
tion, T1 mapping was performed before contrast injection
using the same acquisition (2D FLASH) and a range of flip
angles (3°, 5°, 7°, 10°, 15°, 17°, 24°, 31°). The MRI parame-
ters for the two sequences were as follows: TE/TR = 2.10/
15.00 ms, 1 average, matrix = 96 × 96, FOV = 25 × 25
mm2, resolution = 260 × 260 μm2, slice thick-
ness = 75 μm. Two slices were acquired, one through the
masseter muscle and one along the external jugular vein
for assessment of arterial input function.
4.2.4 | Investigation of the effect of histamine
The animals received saline on the first day and histamine
on the following day as a volume of 150 μL of either sal-
ine (control) or histamine (dose 0.2 mmol/kg body weight
BW)19 into the tail vein during 10 seconds using an injec-
tion pump. Although starting with the dosage given by19,
we had to reduce it to 0.2 mmol/kg which was the highest
tolerated by the mice used in this study. Each animal was
imaged either with Dotarem (Gd‐DOTA, molecular weight
0.56 kDa) or Gadomer‐17 contrast agent (molecular weight
17 kDa, but with Stokes radius corresponding to a globular
protein of molecular weight 30‐35 kDa). Both contrast
agents were injected at 0.44 mmol Gd/kg bw. Dotarem was
injected in a mean volume of 120 μL. In order to achieve
the gadolinium dose for Gadomer, it had to be injected in
an average volume of for and Gadomer‐17 in a mean vol-
ume of 300 μL. The contrast agent was injected 1.5 min-
utes after the injection of saline or histamine via the mouse
tail vein over a period of 15 seconds using an MRI‐com-
patible programmable injection pump (Harvard Apparatus,
Massachusetts, USA). The control experiments with saline
were performed 1 day before the experiments with his-
tamine.
4.3 | Experimental groups
4.3.1 | Effect of histamine in wild type mice
Seven mice received saline followed by Dotarem 1.5 min-
utes later and MRI signals were recorded as described
above. The i.v. catheter was removed and the mice woke
up within minutes after cessation anaesthesia. On the sub-
sequent day, the same seven mice received first histamine
and then Dotarem 1.5 minutes later with MRI recording as
described above. After this recording and while still anaes-
thetized, the mice were killed by breaking their stretched
neck with a blunt stroke with a pair of scissors. Eight other
mice underwent the same procedure but received Gadomer‐
17 instead of Dotarem.
4.3.2 | Effect of histamine in Epac1−/− mice
The procedures were exactly as described above for wt
mice. On day one for the Dotarem studies, 10 Epac1−/−
mice received saline followed by Dotarem 1.5 minutes later
and the MRI signal was recorded as described. The i.v.
catheter was removed and anaesthesia was terminated and
the mice woke up within minutes. On the subsequent day,
the same mice received histamine prior to Dotarem and the
MRI signal was recorded as described. After the recording
and while still anaesthetized, the mice were killed as
described above. Twelve other mice underwent the same
procedure as the first 10 mice, but received Gadomer‐17
instead of Dotarem.
4.3.3 | Comparison of Dotarem and
Gadomer-17 in the same mouse
Six mice received saline followed by Dotarem 1.5 minutes
later and the MRI signal was recorded as described. The i.v.
catheter was removed and the mice woke up within minutes
after cessation of anaesthesia. On the following day,
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Gadomer‐17 was given after saline as described and record-
ing of the MRI signal started 1.5 minutes later. The mice
were killed while still anaesthetized as described above.
4.4 | Numerical models for analysis of the
MRI signal
4.4.1 | Model parameters
In previous studies, we used a modified two‐compartmental
model to extract estimates of the rate constant for blood‐to‐
tissue exchange (PS/Va) for Gadomer‐17 in mice exposed
to ANP.3,5 PS is the permeability‐surface area product and
Va is the local microvascular volume. This model makes
simplifying assumptions about the ratio (Va/S) and gradi-
ents of tracer concentration across a microvascular bed to
estimate permeability coefficients during vascular perfu-
sion. These assumptions may be compromised when more
permeable lower molecular weight tracers such as Dotarem
are used or when both permeability and blood flow are
increased by an inflammatory agent.
We therefore also tested an alternate approach based on
the classical Kety/Renkin/Crone model of tracer extraction
in a perfused microvessel. The extraction fraction (E) is
defined as (Ca−Cv)/Ca where the Ca is the arterial tracer
concentration and Cv is the tracer on the venular side of
the microvasculature bed. E is determined by both plasma
flow (Fp) and the product of permeability coefficient P and
surface area (S) product:
E ¼ 1 expðPS=FpÞ (1)
The Johnson‐Wilson form of this model requires high
extraction fraction of the tracer and rapid tracer equilibra-
tion in the extravascular space. It takes into account the
volume (Ve) of the extracellular space available to the tra-
cer and exchange between the tissue and the plasma is
described in terms of exchange rate constant kep.
7
Kep ¼ EFb=Ve (2)
In previous publications, detailed evaluations of decon-
volution methods (advanced curved fitting) have been
described to evaluate the Johnson‐Wilson model and tested
using Dotarem as a tracer. The approach enables estimation
of four model parameters that describe tissue uptake: The
transvascular transit time Tc, plasma flow rate Fp as well as
E and kep.
20–22 Blood flow is calculated as Fp/(1‐Hct)
where Hct was set at 40%. The parameters, permeability‐
surface area product, PS, local vascular volume for the tra-
cer in a region‐of‐interest (ROI) (Va), extracellular volume
available to the tracer (Ve) and a tracer clearance term ktrans
are then derived from these estimates. The increase in the
number of parameters in the Johnson‐Wilson model analy-
sis introduces additional parameter sensitivities to both
noise in the data and signal strength when physiological
changes are relatively small.
4.4.2 | Deconvolution methods
The analysis of the time course of the SI curves from MRI
experiments in mice using an arterial input function (AIF)
and a tissue residue function (TRF) was derived from the
Johnson‐Wilson exchange model.7,20–22 Briefly, the analy-
sis describes the observed sequence of the DCE‐MRI tissue
signal intensity (St) in terms of n iteration steps where
St(n) = Cp (n)*H(n). Here, Cp(n) is the AIF and H(n) is the
TRF multiplied by the Fb. Successive updates of both the
TRF and then the AIF functions are made until conver-
gence as described.22
For the JW model, the vascular phase is
HðnÞ ¼ Fp<nTs<Tc
where Ts is the sampling interval and Tc is the mean
intravascular transit time.
The tissue phase is
HðnÞ ¼ Vekep expðkepnTsÞ; nTs>Tc (3)
From the analysis,20 values of kep, E and Fp are
obtained for a user defined range of Tc.
Previous evaluations of the method have demonstrated
that attempts to obtain an AIF from measurements of the
changes in SI of a tracer over a small artery separate from the
signal over the tissue were not successful in the mouse,
whereas an AIF determined from the so‐called blind decon-
volution approach converges. A particular advantage of the
blind deconvolution method is that only the integral of the
AIF is needed for the analysis. This reduces the dependence
on noise due to respiratory and vascular disturbances on the
AIF. However, the evaluation of this integral from the area
under the SI measured over the tissue requires an indepen-
dent estimate of the volume of distribution of the tracer in
the vascular and extravascular compartments in a given
organ. For a molecule of the size and properties of Dotarem,
the distribution volume is about 0.12 mL mL−1 of muscle
tissue.22,23 No independent measurement of this distribution
volume is available for Gadomer‐17, but its apparent molec-
ular weight would indicate that it is similar to that of albumin
(cf, ref. 23). Because of its high molecular weight and low
permeability in muscle tissue, Gadomer‐17 tracer distribution
is biased towards the vascular volume.
4.4.3 | Analysis based on two compartment
model
The compartmental model is developed from the so‐called
step‐slope analysis. The analysis was first developed for
12 of 14 | CURRY ET AL.
fluorescently labelled tracers in individually perfused
microvessels24 and later modified for fluorescent and MRI
measurements in mice.5,25
The simplest analysis of the SI vs time curve is based
on the assumption that, after filling the vasculature, tracer
accumulation is in the extravascular space and is driven by
the concentration difference of tracer between plasma and
interstitial fluid.
Tracer accumulation in the extravascular volume Ve was
described by Ficks Law:
VtðdCt=dtÞ ¼ PSðCa;mean  Ct;meanÞ (4)
where Ca, mean and Ct, mean are the average tracer concen-
tration on the vascular and extravascular compartments.
The fall in Ca(t) with time was approximated by a first‐
order fall in tracer concentration towards a quasi‐equilib-
rium in the body described by the relation:
ðCðtÞ  CequilÞ=ðC0  CequilÞ  expðkarttÞ (5)
where Cequil = 0.27 Co assuming a whole body the extravas-
cular space that was 2.7 times larger than the vascular space
and the combined distribution space is 3.7 times the initial
distribution space and kart is the rate constant. We tried to
derive initial estimates of kart for Dotarem from the SI mea-
sured over an adjacent blood vessel flowing near the mea-
suring window within the masseter muscle but, as with the
deconvolution analysis, this approach was not successful
because the values were quite variable and the estimated val-
ues were too large to account for the initial rate of fall SI
intensity over the measuring window after the step increase
in signal intensity. The values of kart are therefore adjusted
independently to fit data for each animal.
For Dotarem, which was expected to be filtered freely
in the kidney, an additional term was needed to describe
the continued fall in arterial tracer concentration after the
initial rapid distribution of the tracer towards a quasi‐equi-
librium between plasma and body tissues. This was set
equal to the first‐order time constant equal to GFR divided
by whole body plasma volume. Unpublished measurements
of mean GFR in these mice from one of our labs (SOD)
are 220 μL min−1 in wt mice and 275 μL min−1 in
Epac1−/− or 7.3 and 9.2 μL min/g BW respectively. Whole
body plasma volumes are 30‐35 μL/g BW for both wt and
Epac1−/− mice, giving rate constant for renal excretion of
Dotarem 0.0036 s−1 and 0.0046 s−1 for wt and Epac1−/−
mice respectively. Thus, for Dotarem, the fall in arterial
concentration at each interval in time in wt mice was calcu-
lated from Equation 5 with the additional correction for
renal excretion with a time constant of −0.0036 s−1.
The accumulation was calculated by numerical integra-
tion where total accumulation relative to the initial amount
equals (VaCa (t) + VeCt)/VaCt (0).
For completeness, the rate constant for renal or other
non‐specific Gadomer‐17 loss was arbitrarily set at 5% of
the Dotarem renal excretion rate. The compartmental model
is similar to the diffusion‐limited compartmental model
used in previous analyses.26
4.5 | Statistical analysis
Data are presented as mean ± 1 SD. Statistical significance
within each experimental group (Groups A, B and C) was
investigated using two‐tailed Student's t test for paired
comparison when analysing the effect of i.v. histamine vs
i.v. saline as well as in Group C when comparing Dotarem
and Gadomer‐17 in the same mouse. Comparison between
wt vs Epac1−/− (Groups A and B) was done with two‐
tailed t test for independent groups. P < 0.05 was consid-
ered statistically significant.
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